Published Online: March 5, 2015. doi:10.1001/jama.2015.1995.
Study concept and design: Lai, Davey, Beck, Rogers, Rubinson, Mulligan.
Acquisition, analysis, or interpretation of data: Lai, Davey, Beck, Xu, Suffredini, Palmore, Kabbani, Kobinger, Ströher, Wolcott, Dorman, Uyeki, Feldmann, Lane, Mulligan.
Drafting of the manuscript: Lai, Davey, Suffredini, Rubinson, Wolcott, Uyeki, Mulligan.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, or material support: Lai, Davey, Beck, Xu, Suffredini, Palmore, Kabbani, Alimonti, Link, Ströher, Wolcott, Dorman, Uyeki, Feldmann, Mulligan.
Study supervision: Lane, Mulligan.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Link reported receiving grant funding from the National Institutes of Health, NewLink Genetics, and the US Department of Defense; and being founder and CEO of NewLink Genetics. Dr Ströher reported being an inventor and patent holder of a recombinant vesicular stomatitis vaccine. Dr Feldmann reported being a patent holder of a recombinant vesicular stomatitis vaccine. No other disclosures were reported.
Funding/Support: This work was supported in part by the Georgia Research Alliance and Emory University (Dr Mulligan); the National Center for Advancing Translational Sciences of the National Institutes of Health (award UL1TR000454); the Emory Vaccinology Training Program under the National Institute of Allergy and Infectious Diseases, National Institutes of Health (T32AI074492 awarded to Drs Kabbani and Mulligan); and the National Institute of Allergy and Infectious Diseases Intramural Research Program at the National Institutes of Health.
Role of the Funder/Sponsor: These supporting organizations had no role in the design and conduct of the work; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases, or the US Army.
Additional Information: We thank the patient for providing permission to share his information.
Additional Contributions: We acknowledge the following contributors for their invaluable assistance: Samantha Tostenson, BA (US Army Medical Research Institute of Infectious Diseases), for technical assistance with samples; Gene Olinger, PhD, and the Integrated Research Facility Clinical Core, Division of Clinical Research (National Institute of Allergy and Infectious Diseases, National Institutes of Health) for sample processing; Vance Ferebee, BSN, and Jonathan Jackson, RN, for nursing care on the jet (Phoenix Air); Wellington Sun, MD (US Food and Drug Administration), and Rebecca Rousselle, BA, and Maria Davila, MD (Emory University institutional review board), for emergency regulatory approvals; Chinglai Yang, PhD (Emory University), for recombinant Ebola VP40 matrix protein; Jiusheng Deng, PhD (Emory University), for technical assistance with the cytokine data; BobbieRae Erickson, MPH, and Amy Schuh, PhD, for assistance with real-time reverse transcription–polymerase chain reaction (US Centers for Disease Control and Prevention); the nursing and medical staff of the Special Clinical Studies Unit for their care of the patient; Yael Rosenberg-Hasson, PhD (Human Immune Monitoring Center at Stanford University), for performance of the cytokine assays; and Jay Ramsey, PhD (NewLink Genetics), for assistance with vaccine acquisition. We also thank Dorothea Blandford, PhD, and the Public Health Agency of Canada for providing the VSVΔG-ZEBOV vaccine. No compensation was received by any of the persons named in this section.